However, tumors that are negative for ER, PR, and HER-2 markers, referred to as triple-negative breast cancer (TNBC), account for about 20% of breast cancer in the Unites States and have a disproportionate share of the morbidity and mortality. Here, ERBB2 is linked to breast carcinoma.